References
1. Rankin A, Cadogan CA, Patterson SM, Kerse N, Cardwell CR, Bradley MC, Ryan C, Hughes C: Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2018, 9:CD008165.
2. Gutierrez-Valencia M, Izquierdo M, Cesari M, Casas-Herrero A, Inzitari M, Martinez-Velilla N: The relationship between frailty and polypharmacy in older people: A systematic review. Br J Clin Pharmacol 2018, 84(7):1432-1444.
3. Fried TR, O’Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK: Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc 2014, 62(12):2261-2272.
4. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K: Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol 2010, 69(5):543-552.
5. Motter FR, Fritzen JS, Hilmer SN, Paniz EV, Paniz VMV: Potentially inappropriate medication in the elderly: a systematic review of validated explicit criteria. Eur J Clin Pharmacol 2018, 74(6):679-700.
6. Storms H, Marquet K, Aertgeerts B, Claes N: Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: A systematic review. Eur J Gen Pract 2017, 23(1):69-77.
7. O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P: STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing 2015, 44(2):213-218.
8. By the American Geriatrics Society Beers Criteria Update Expert P: American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc2015, 63(11):2227-2246.
9. Hanlon JT, Schmader KE, Samsa GP, Weinberger M, Uttech KM, Lewis IK, Cohen HJ, Feussner JR: A method for assessing drug therapy appropriateness. J Clin Epidemiol 1992, 45(10):1045-1051.
10. Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E, Colloca G et al : International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 2014, 32(24):2595-2603.
11. Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S, Castillo D, Sharma M, Holmes HM, Nightingale G et al : Associations of Polypharmacy and Inappropriate Medications with Adverse Outcomes in Older Adults with Cancer: A Systematic Review and Meta-Analysis.Oncologist 2020, 25(1):e94-e108.
12. Maggiore RJ, Gross CP, Hurria A: Polypharmacy in older adults with cancer. Oncologist 2010, 15(5):507-522.
13. Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM: Polypharmacy and potentially inappropriate medication use in geriatric oncology.J Geriatr Oncol 2016, 7(5):346-353.
14. LeBlanc TW, McNeil MJ, Kamal AH, Currow DC, Abernethy AP: Polypharmacy in patients with advanced cancer and the role of medication discontinuation. Lancet Oncol 2015, 16(7):e333-341.
15. Lees J, Chan A: Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol 2011, 12(13):1249-1257.
16. Oldak S, Ioannou S, Kamath P, Huang M, George S, Slomovitz B, Schlumbrecht M: Polypharmacy in Patients with Ovarian Cancer.Oncologist 2019, 24(9):1201-1208.
17. Hong S, Lee JH, Chun EK, Kim KI, Kim JW, Kim SH, Lee YG, Hwang IG, Kim JY, Koh SJ et al : Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. Oncologist 2019.
18. Calip GS, Xing S, Jun DH, Lee WJ, Hoskins KF, Ko NY: Polypharmacy and Adherence to Adjuvant Endocrine Therapy for Breast Cancer. J Oncol Pract 2017, 13(5):e451-e462.
19. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, Japan Cancer Surveillance Research G: Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project.Jpn J Clin Oncol 2014, 44(4):388-396.
20. Little AG, Gay EG, Gaspar LE, Stewart AK: National survey of non-small cell lung cancer in the United States: epidemiology, pathology and patterns of care. Lung Cancer 2007, 57(3):253-260.
21. Health USNIo: SEER Cancer Stat Facts.
22. Tamura T, Kurishima K, Nakazawa K, Kagohashi K, Ishikawa H, Satoh H, Hizawa N: Specific organ metastases and survival in metastatic non-small-cell lung cancer. Mol Clin Oncol 2015, 3(1):217-221.
23. Salz T, Lavery JA, Lipitz-Snyderman AN, Boudreau DM, Moryl N, Gillespie EF, Korenstein D: Trends in Opioid Use Among Older Survivors of Colorectal, Lung, and Breast Cancers. J Clin Oncol 2019, 37(12):1001-1011.
24. Hasegawa T, Oguri T, Osawa T, Sawa T, Osaga S, Okuyama T, Uchida M, Maeno K, Fukuda S, Nishie H et al : Opioid Dose and Survival of Patients with Incurable Nonsmall Cell Lung Cancer: A Prospective Cohort Study. J Palliat Med 2018, 21(10):1436-1441.
25. Sutradhar R, Lokku A, Barbera L: Cancer survivorship and opioid prescribing rates: A population-based matched cohort study among individuals with and without a history of cancer. Cancer 2017, 123(21):4286-4293.
26. Vora N, Reckamp KL: Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol 2008, 35(6):590-596.
27. Todd A, Williamson S, Husband A, Baqir W, Mahony M: Patients with advanced lung cancer: is there scope to discontinue inappropriate medication? Int J Clin Pharm 2013, 35(2):181-184.
28. Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S et al : Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Eur J Cancer 2017, 84:212-218.
29. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF, Jr., Travis WD et al : The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.J Thorac Oncol 2015, 10(7):990-1003.
30. Feuth T: [The start of 2 levels of competence–from the viewpoint of professional content and organization]. TVZ1992(10):371-375.
31. Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeno J, Dingemans AC, Kim HR, Kim JH, Krebs MG et al : The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol 2018, 84(6):1156-1169.
32. Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R: FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 2005, 10(7):461-466.
33. Wind S, Schnell D, Ebner T, Freiwald M, Stopfer P: Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. Clin Pharmacokinet 2017, 56(3):235-250.
34. Maggiore RJ, Dale W, Gross CP, Feng T, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A et al : Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment. J Am Geriatr Soc 2014, 62(8):1505-1512.
35. Park JW, Roh JL, Lee SW, Kim SB, Choi SH, Nam SY, Kim SY: Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer.J Cancer Res Clin Oncol 2016, 142(5):1031-1040.
36. Raijmakers NJ, van Zuylen L, Furst CJ, Beccaro M, Maiorana L, Pilastri P, Rossi C, Flego G, van der Heide A, Costantini M: Variation in medication use in cancer patients at the end of life: a cross-sectional analysis. Support Care Cancer 2013, 21(4):1003-1011.
37. Sasaki T, Fujita K, Sunakawa Y, Ishida H, Yamashita K, Miwa K, Saji S, Kato Y, Sasaki Y: Concomitant polypharmacy is associated with irinotecan-related adverse drug reactions in patients with cancer.Int J Clin Oncol 2013, 18(4):735-742.
38. Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D et al : Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget 2016, 7(48):80083-80090.
39. Kotlinska-Lemieszek A, Paulsen O, Kaasa S, Klepstad P: Polypharmacy in patients with advanced cancer and pain: a European cross-sectional study of 2282 patients. J Pain Symptom Manage 2014, 48(6):1145-1159.
40. Cashman J, Wright J, Ring A: The treatment of co-morbidities in older patients with metastatic cancer. Support Care Cancer 2010, 18(5):651-655.
41. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J: Methods for estimating the occurrence of polypharmacy by means of a prescription database.Eur J Clin Pharmacol 1997, 53(1):7-11.
42. Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383.
43. Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994, 47(11):1245-1251.
44. Elixhauser A, Steiner C, Harris DR, Coffey RM: Comorbidity measures for use with administrative data. Med Care 1998, 36(1):8-27.
45. Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP, Ganem G, Tubiana-Mathieu N, Gisserot O, Pujade-Lauraine E: Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study.Ann Oncol 2005, 16(11):1795-1800.
46. Elliot K, Tooze JA, Geller R, Powell BL, Pardee TS, Ritchie E, Kennedy L, Callahan KE, Klepin HD: The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res 2014, 38(10):1184-1190.
47. Page RL, 2nd, Linnebur SA, Bryant LL, Ruscin JM: Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions. Clin Interv Aging 2010, 5:75-87.
48. Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, Takahashi K, Fujita Y, Harada T, Minato K et al : Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. J Clin Oncol 2020, 38(2):115-123.
49. Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K et al : Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.Lancet Oncol 2019, 20(5):625-635.
50. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodriguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi Fet al : Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018, 378(24):2288-2301.
51. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B et al : Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. N Engl J Med 2020, 382(1):41-50.
52. Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS et al : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 2017, 376(7):629-640.